Morquio A syndrome-associated mutations: a review of alterations in the GALNS gene and a new locus-specific database

Hum Mutat. 2014 Nov;35(11):1271-9. doi: 10.1002/humu.22635. Epub 2014 Sep 17.

Abstract

Morquio A syndrome (mucopolysaccharidosis IVA) is an autosomal recessive disorder that results from deficient activity of the enzyme N-acetylgalactosamine-6-sulfatase (GALNS) due to alterations in the GALNS gene, which causes major skeletal and connective tissue abnormalities and effects on multiple organ systems. The GALNS alterations associated with Morquio A are numerous and heterogeneous, and new alterations are continuously identified. To aid detection and interpretation of GALNS alterations, from previously published research, we provide a comprehensive and up-to-date listing of 277 unique GALNS alterations associated with Morquio A identified from 1,091 published GALNS alleles. In agreement with previous findings, most reported GALNS alterations are missense changes and even the most frequent alterations are relatively uncommon. We found that 48% of patients are assessed as homozygous for a GALNS alteration, 39% are assessed as heterozygous for two identified GALNS alterations, and in 13% of patients only one GALNS alteration is detected. We report here the creation of a locus-specific database for the GALNS gene (http://galns.mutdb.org/) that catalogs all reported alterations in GALNS to date. We highlight the challenges both in alteration detection and genotype-phenotype interpretation caused in part by the heterogeneity of GALNS alterations and provide recommendations for molecular testing of GALNS.

Keywords: GALNS; MPS IVA; Morquio A; lysosomal storage disorder; mucopolysaccharidosis type IVA.

Publication types

  • Review

MeSH terms

  • Alleles
  • Animals
  • Biomarkers
  • Chondroitinsulfatases / genetics*
  • Databases, Nucleic Acid*
  • Disease Models, Animal
  • Gene Frequency
  • Genetic Association Studies
  • Genotype
  • Geography
  • Humans
  • Infant, Newborn
  • Mucopolysaccharidosis IV / diagnosis
  • Mucopolysaccharidosis IV / genetics*
  • Mucopolysaccharidosis IV / therapy
  • Mutation*
  • Neonatal Screening
  • Phenotype
  • Quantitative Trait Loci

Substances

  • Biomarkers
  • Chondroitinsulfatases
  • GALNS protein, human